MARKET

OSUR

OSUR

OraSure Tech
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.65
+0.41
+3.65%
After Hours: 11.65 0 0.00% 13:56 11/27 EST
OPEN
11.37
PREV CLOSE
11.24
HIGH
11.78
LOW
11.27
VOLUME
662.95K
TURNOVER
--
52 WEEK HIGH
19.75
52 WEEK LOW
5.23
MARKET CAP
833.66M
P/E (TTM)
-51.3442
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
FDA authorizes first at-home rapid COVID-19 test
The FDA has issued an emergency use authorization ((EUA)) to the single-use COVID-19 diagnostic test kit from Lucira Health, a California manufacturer.The Lucira COVID-19 All-In-One at home test kit provides rapid results. To date,
Seekingalpha · 11/18 05:20
OraSure Technologies to Present at the Stephens Annual Investment Conference 2020
BETHLEHEM, Pa., Nov. 12, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, and microbiome laboratory and analytical services, today announced that Dr. Stephen S. Tang, President and CEO, will speak to the investment community at the Stephens Annual Investment Conference 2020. The conference will be simultaneously webcast over the Internet. Dr. Tang is scheduled to speak on November 19, 2020, at approximately 8:00 AM Eastern Standard Time (5:00 AM Pacific Time). Interested investors can access the live webcast of the presentation by going to OraSure Technologies’ web site, www.orasure.com and clicking on the Investor Info link. A replay of the webcast will be available on OraSure Technologies’ web site for seven days. Alternatively, you can access the live webcast of the presentation via the following link: https://kvgo.com/stephens/orasure-november-2020 About OraSure TechnologiesOraSure Technologies empowers the global community to improve health and wellness by providing access to accurate, essential information. Together with its wholly-owned subsidiaries, DNA Genotek, Diversigen, CoreBiome (now operating under the Diversigen brand), UrSure and Novosanis, OraSure provides its customers with end-to-end solutions that encompass tools, services and diagnostics. The OraSure family of companies is a leader in the development, manufacture, and distribution of rapid diagnostic tests, sample collection and stabilization devices, and molecular services solutions designed to discover and detect critical medical conditions. OraSure’s portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharma, commercial entities and direct to consumers. For more information on OraSure Technologies, please visit www.orasure.com.Company contacts: Sam Martin Argot Partners 212-600-1902 OraSure@argotpartners.comJeanne Mell VP Corporate Communications 484-353-1575 media@orasure.com www.orasure.com
GlobeNewswire · 11/12 12:00
Clinical Reference Laboratory to Market Most Cost-Effective, Gold-Standard Self-Collected COVID-19 Saliva Test Directly to Consumers
Today, Clinical Reference Laboratory (CRL), one of the largest privately held clinical testing laboratories in the U.S., announced that it has begun selling its best-in-class CRL Rapid Response™ saliva-based COVID-19 RT-PCR test directly to consumers. At $110 (which includes the cost of prepaid FedEx Priority Overnight shipping in both directions), the easy-to-use, highly accurate test is one of the most affordable COVID-19 home tests currently available in the market and the least expensive at-home saliva test.
PR Newswire · 11/09 13:02
ACB, BLUE, SD and UPWK among midday movers
Gainers: Altus Midstream (ALTM) +150%.Hall of Fame Resort & Entertainment (HOFV) +118%.Oncternal Therapeutics (ONCT) +82%.Upwork (UPWK) +41%.Aptevo Therapeutics (APVO) +40%.Resideo Technologies (REZI) +35%.Aurora Cannabis (ACB) +34%.Kaixin Auto (KXIN) +33%.Falcon Minerals (FLMN) +28%.SandRidge Energy
Seekingalpha · 11/05 17:43
OraSure Technologies Q3 EPS $0.01 Beats $(0.07) Estimate, Sales $48.01M Beat $41.70M Estimate
OraSure Technologies (NASDAQ:OSUR) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.07) by 114.29 percent. This is a 95.24 percent decrease over earnings of $0.21 per share
Benzinga · 11/04 21:17
OraSure Technologies EPS beats by $0.08, beats on revenue, Q4 revenue guidance
OraSure Technologies (OSUR): Q3 GAAP EPS of $0.01 beats by $0.08.Revenue of $48M (+33.4% Y/Y) beats by $8.8M.Q4 guidance: Net revenues of $55M-$60M vs consensus of $55.6M.Shares -5.3%.Press Release
Seekingalpha · 11/04 21:13
OraSures DNA Genotek Subsidiary Receives FDA Emergency Use Authorization for its ORAcollect®·RNA Saliva Collection Device for SARS CoV-2
Second FDA EUA for the Subsidiary’s Saliva Collection DevicesBETHLEHEM, Pa., Nov. 03, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced its DNA Genotek subsidiary has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the use of the ORAcollect®·RNA (OR/ORE-100) saliva collection device for the collection, stabilization and transport of saliva specimens suspected of containing SARS-CoV-2 RNA. This is the second FDA EUA that DNA Genotek has received for its saliva collection devices. Like the EUA DNA Genotek recently obtained for OMNIgene®·ORAL (OM/OME-505), this EUA allows for the unsupervised use of the device at-home or in a healthcare setting when used as a component of an authorized or cleared self-collection kit. This means it can be part of a kit that is authorized under its own EUA for use by an individual to collect saliva specimens at home.“Accessible and accurate testing programs that include a non-invasive, saliva-based collection option will be essential throughout the duration of the COVID-19 pandemic,” said Kathleen Weber, Executive Vice President, Business Unit Leader, Molecular Solutions at DNA Genotek. “This second EUA gives our customers additional non-invasive options for SARS CoV-2 sample collection. Saliva sample collection is quick, painless, non-invasive and requires less human contact both minimizing the need for PPE and reducing exposure to potentially infected patients.”The ORAcollect·RNA collection device is an important component of molecular/PCR tests as laboratories are able to use it as the saliva sample collection method for their COVID-19 tests.In addition to molecular sample collection devices for lab-based molecular/PCR COVID-19 testing from its DNA Genotek subsidiary, OraSure is also developing a lab-based oral fluid SARS-CoV-2 antibody test, and a rapid antigen self-test for COVID-19.The ORAcollect·RNA and OMNIgene·ORAL sample collection devices have not been FDA cleared or approved; the devices have been authorized by FDA under an EUA. The ORAcollect·RNA and OMNIgene·ORAL sample collection devices have been authorized only to collect, stabilize, and maintain during transport, saliva specimens suspected of containing SARS-CoV-2 ribonucleic acid (RNA), not for any other viruses or pathogens; and the ORAcollect·RNA and OMNIgene·ORAL sample collection devices are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in medical devices during the COVID-19 outbreak under Section564(b)(1) of the Federal Food, Drug, and Cosmetic Act,21U.S.C. §360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.About OraSure Technologies OraSure Technologies empowers the global community to improve health and wellness by providing access to accurate, essential information. Together with its wholly-owned subsidiaries, DNA Genotek, Diversigen, CoreBiome (now operating under the Diversigen brand), UrSure and Novosanis, OraSure provides its customers with end-to-end solutions that encompass tools, services and diagnostics. The OraSure family of companies is a leader in the development, manufacture, and distribution of rapid diagnostic tests, sample collection and stabilization devices, and molecular services solutions designed to discover and detect critical medical conditions. OraSure’s portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharma, commercial entities and direct to consumers. For more information on OraSure Technologies, please visit www.orasure.com.About DNA Genotek DNA Genotek Inc., a subsidiary of OraSure Technologies, Inc., focuses on providing high-quality biological sample collection products and end-to-end services for human genomics and microbiome applications. The Company's Oragene®•Dx and ORAcollect®•Dx product lines are the first and only FDA 510(k) cleared saliva-based DNA collection devices for in vitro diagnostic use. DNA Genotek also offers Research Use Only products to collect and preserve large amounts of DNA or RNA from multiple sample types. DNA Genotek markets its products worldwide and has a global customer base with thousands of customers in over 100 countries. For more information about DNA Genotek, visit www.dnagenotek.com.Important Information This press release contains certain forward-looking statements, including with respect to expected revenues and earnings/loss per share. Forward-looking statements are not guarantees of future performance or results. Known and unknown factors that could cause actual performance or results to be materially different from those expressed or implied in these statements include, but are not limited to: ability to successfully manage and integrate acquisitions of other companies in a manner that complements or leverages our existing business, or otherwise expands or enhances our portfolio of products and our end-to-end service offerings, and the diversion of management’s attention from our ongoing business and regular business responsibilities to effect such integration; the expected economic benefits of acquisitions (and increased returns for our stockholders), including that the anticipated synergies, revenue enhancement strategies and other benefits from the acquisitions may not be fully realized or may take longer to realize than expected and our actual integration costs may exceed our estimates; impact of increased or different risks arising from the acquisition of companies located in foreign countries; ability to market and sell products, whether through our internal, direct sales force or third parties; impact of significant customer concentration in the genomics business; failure of distributors or other customers to meet purchase forecasts, historic purchase levels or minimum purchase requirements for our products; ability to manufacture products in accordance with applicable specifications, performance standards and quality requirements; ability to obtain, and timing and cost of obtaining, necessary regulatory approvals for new products or new indications or applications for existing products; ability to comply with applicable regulatory requirements; ability to effectively resolve warning letters, audit observations and other findings or comments from the U.S. Food and Drug Administration (“FDA”) or other regulators; the impact of the novel coronavirus (“COVID-19”) pandemic on our business and our ability to successfully develop new products, validate the expanded use of existing collector products and commercialize such products for COVID-19 testing; changes in relationships, including disputes or disagreements, with strategic partners or other parties and reliance on strategic partners for the performance of critical activities under collaborative arrangements; ability to meet increased demand for the Company’s products; impact of replacing distributors; inventory levels at distributors and other customers; ability of the Company to achieve its financial and strategic objectives and continue to increase its revenues, including the ability to expand international sales; ability to identify, complete, integrate and realize the full benefits of future acquisitions; impact of competitors, competing products and technology changes; reduction or deferral of public funding available to customers; competition from new or better technology or lower cost products; ability to develop, commercialize and market new products; market acceptance of oral fluid or urine testing, collection or other products; market acceptance and uptake of microbiome informatics, microbial genetics technology and related analytics services; changes in market acceptance of products based on product performance or other factors, including changes in testing guidelines, algorithms or other recommendations by the Centers for Disease Control and Prevention (“CDC”) or other agencies; ability to fund research and development and other products and operations; ability to obtain and maintain new or existing product distribution channels; reliance on sole supply sources for critical products and components; availability of related products produced by third parties or products required for use of our products; impact of contracting with the U.S. government; impact of negative economic conditions; ability to maintain sustained profitability; ability to utilize net operating loss carry forwards or other deferred tax assets; volatility of the Company’s stock price; uncertainty relating to patent protection and potential patent infringement claims; uncertainty and costs of litigation relating to patents and other intellectual property; availability of licenses to patents or other technology; ability to enter into international manufacturing agreements; obstacles to international marketing and manufacturing of products; ability to sell products internationally, including the impact of changes in international funding sources and testing algorithms; adverse movements in foreign currency exchange rates; loss or impairment of sources of capital; ability to attract and retain qualified personnel; exposure to product liability and other types of litigation; changes in international, federal or state laws and regulations; customer consolidations and inventory practices; equipment failures and ability to obtain needed raw materials and components; the impact of terrorist attacks and civil unrest; and general political, business and economic conditions. These and other factors that could affect our results are discussed more fully in our SEC filings, including our registration statements, Annual Report on Form 10-K for the year ended December 31, 2019, Quarterly Reports on Form 10-Q, and other filings with the SEC. Although forward-looking statements help to provide information about future prospects, readers should keep in mind that forward-looking statements may not be reliable. Readers are cautioned not to place undue reliance on the forward-looking statements. The forward-looking statements are made as of the date of this press release and OraSure Technologies undertakes no duty to update these statements.Investor Contact:Media Contact: Sam MartinJeanne Mell Argot PartnersVP Corporate Communications 212-600-1902484-353-1575 orasure@argotpartners.commedia@orasure.com
GlobeNewswire · 11/03 12:00
OraSure's Emergency Use Authorization, And Other News: The Good, Bad And Ugly Of Biopharma
OraSure receives emergency use authorization for OMNIgene.Keros Therapeutics initiates Phase 2 clinical trial for Myelodysplastic Syndromes.Affimed to collaborate with NKMax America for SNK01 natural killer cell therapy.
Seekingalpha · 10/22 11:26
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of OSUR. Analyze the recent business situations of OraSure Tech through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average OSUR stock price target is 19.29 with a high estimate of 34.00 and a low estimate of 13.00.
EPS
Institutional Holdings
Institutions: 307
Institutional Holdings: 76.29M
% Owned: 106.61%
Shares Outstanding: 71.56M
TypeInstitutionsShares
Increased
71
6.86M
New
64
3.92M
Decreased
47
8.41M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+1.62%
Healthcare Equipment & Supplies
+1.44%
Key Executives
Chairman/Independent Director
Michael Celano
President/Chief Executive Officer/Director
Stephen Tang
Chief Financial Officer
Roberto Cuca
Executive Vice President
Lisa Nibauer
Executive Vice President
Kathleen Weber
Senior Vice President/Chief Compliance Officer/General Counsel/Secretary
Jack Jerrett
Vice President - Finance/Controller
Michele Miller
Director
Lelio Marmora
Independent Director
Mara Aspinall
Independent Director
James Datin
Independent Director
Eamonn Hobbs
Independent Director
Ronny Lancaster
Independent Director
David Shulkin
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About OSUR
OraSure Technologies, Inc. (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types. The Company operates in two segments: OSUR and DNAG. OSUR consists of the development, manufacture and sale of diagnostic products, specimen collection devices, and medical devices. DNAG or molecular collection systems business consists primarily of the development, manufacture and sale of oral fluid collection devices that are used to collect, stabilize, and store samples of genetic material for molecular testing.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of OraSure Technologies, Inc. stock information, including NASDAQ:OSUR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OSUR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OSUR stock methods without spending real money on the virtual paper trading platform.